Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
65.19 ^USD	-0.58%		-1.17%	+3.81%

08/05	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/04	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT

Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 02:42 am IST

Vaxcyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 402.27 million compared to USD 223.49 million a year ago. Basic loss per share from continuing operations was USD 4.14 compared to USD 3.44 a year ago.

Latest news about Vaxcyte, Inc.

Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	26/04	MT
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	23/04	MT
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03	CI
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03	CI
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03	CI
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03	MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating	12/03	MT
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	12/03
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	06/03
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03	CI
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating	28/02	MT
Vaxcyte Q4 Loss Widens	28/02	MT
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024	28/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	03/02	MT
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	01/02	MT
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	01/02	MT
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	31/01	MT
Vaxcyte Launches Securities Offering; Shares Fall After Hours	31/01	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	30/01	MT
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate	29/01	MT
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate	29/01	MT
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	29/01	CI
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing	26/01	MT

Chart Vaxcyte, Inc.

Duration

Period

More charts

Company Profile

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Sector

Biotechnology & Medical Research

Calendar

14/05/2024 - BofA Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

65.19 USD

Average target price

103.1 USD

Spread / Average Target

+58.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXCYTE, INC.	+3.81%	7.09B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs